The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer

Japanese Journal of Clinical Oncology

Volumn 41, Issue 4, 2011, Pages 577-581

  Torimoto, Kazumasa ^a   Samma, Shoji ^b   Kagebayashi, Yoriaki ^b   Chihara, Yoshitomo ^a   Tanaka, Nobumichi ^a   Hirayama, Akihide ^a   Fujimoto, Kiyohide ^a   Hirao, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Body composition; Electric impedance; Gonadotropin releasing hormone; Lipid metabolism; Prostatic neoplasms

Indexed keywords

BICALUTAMIDE; GONADORELIN; GOSERELIN; HIGH DENSITY LIPOPROTEIN; LEUPRORELIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY COMPOSITION; CANCER STAGING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; HUMAN; INTRAABDOMINAL FAT; JAPANESE; LIPID METABOLISM; METABOLIC SYNDROME X; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

ADIPOSE TISSUE; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ASIAN CONTINENTAL ANCESTRY GROUP; BODY COMPOSITION; ELECTRIC IMPEDANCE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; INTRA-ABDOMINAL FAT; JAPAN; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 79953743183     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr005     Document Type: Article

References (19)

1. Cooperberg MR, Lubeck DP, Penson DF, Mehta SS, Carroll PR, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol 2003;170:905-8.
2. Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. Jpn J Clin Oncol 2010;40:588-92.
3. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39-46.
4. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-5.
5. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-500.
6. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009;27:92-9.
7. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009;27:3452-8.
8. Hoang KC, Le TV, Wong ND. The metabolic syndrome in East Asians. J Cardiometab Syndr 2007;2:276-82.
9. Bedogni G, Malavolti M, Severi S, Poli M, Mussi C, Fantuzzi AL, et al. Accuracy of an eight-point tactile-electrode impedance method in the assessment of total body water. Eur J Clin Nutr 2002;56: 1143-8.
10. Malavolti M, Mussi C, Poli M, Fantuzzi AL, Salvioli G, Battistini N, et al. Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21-82 years. Ann Hum Biol 2003;30:380-91.
11. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000;163:1743-6.
12. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750-7.
13. Burton BT, Foster WR, Hirsch J, Van Itallie TB. Health implications of obesity: an NIH consensus development conference. Int J Obes 1985;9:155-70.
14. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990;39:897-901.
15. Xu X, De Pergola G, Bjorntorp P. The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology 1990;126:1229-34.
16. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261-7.
17. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599-603.
18. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81:4358-65.
19. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84:2647-53